Condizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: Springer Berlin Heidelberg, 2011
ISBN 10: 364283339X ISBN 13: 9783642833397
Da: moluna, Greven, Germania
EUR 92,27
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New.
Condizione: New.
Da: Ria Christie Collections, Uxbridge, Regno Unito
EUR 146,45
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. In.
Condizione: New. pp. xvi + 296.
Da: Revaluation Books, Exeter, Regno Unito
EUR 156,09
Quantità: 2 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. reprint edition. 312 pages. 10.00x6.00x0.90 inches. In Stock.
EUR 114,36
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The ultimate 'consumer' of the data presented at conferences on the primary treatment of operable breast cancer is the patient, and when, as in this disease, the benefits of therapy are relatively mod est, the availability and interpretation of the data from trials be comes an issue of primary importance. The effects of present treat ment are in fact such that more patients relapse despite therapy than are estimated to benefit from it. It is, therefore, extremely dif ficult for the physician to recommend unequivocally one particular adjuvant treatment modality for the vast population of women with breast cancer. The interpretation of results from clinical research-oriented pro grams is constantly applied, however, in the treatment of breast cancer patients outside of clinical trials. From presented or publish ed data, many physicians extrapolate indications for the use of a given treatment regimen for their patients, perceiving it as the 'best available therapy. ' It is essential that the 'best available therapy' be selected individually for each patient. However, considering the modest effect of treatment upon outcome, it is imperative that those who provide the data - those who are involved in both pa tient care and clinical research - make it known that the best cur rent treatment for the population of breast cancer patients is avail able within the framework of clinical trials. In this way not only present-day patients but also future ones will derive the greatest benefit.
Lingua: Inglese
Editore: Springer Berlin Heidelberg, Springer Berlin, 2011
ISBN 10: 364283339X ISBN 13: 9783642833397
Da: BUCHSERVICE / ANTIQUARIAT Lars Lutzer, Wahlstedt, Germania
EUR 299,90
Quantità: 1 disponibili
Aggiungi al carrelloSoftcover. Condizione: gut. 2011. Adjuvant Therapy of Primary Breast Cancer In deutscher Sprache. pages.
Da: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 86,24
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: new. Questo è un articolo print on demand.
Lingua: Inglese
Editore: Springer, Springer Vieweg Dez 2011, 2011
ISBN 10: 364283339X ISBN 13: 9783642833397
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 106,99
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The ultimate 'consumer' of the data presented at conferences on the primary treatment of operable breast cancer is the patient, and when, as in this disease, the benefits of therapy are relatively mod est, the availability and interpretation of the data from trials be comes an issue of primary importance. The effects of present treat ment are in fact such that more patients relapse despite therapy than are estimated to benefit from it. It is, therefore, extremely dif ficult for the physician to recommend unequivocally one particular adjuvant treatment modality for the vast population of women with breast cancer. The interpretation of results from clinical research-oriented pro grams is constantly applied, however, in the treatment of breast cancer patients outside of clinical trials. From presented or publish ed data, many physicians extrapolate indications for the use of a given treatment regimen for their patients, perceiving it as the 'best available therapy. ' It is essential that the 'best available therapy' be selected individually for each patient. However, considering the modest effect of treatment upon outcome, it is imperative that those who provide the data - those who are involved in both pa tient care and clinical research - make it known that the best cur rent treatment for the population of breast cancer patients is avail able within the framework of clinical trials. In this way not only present-day patients but also future ones will derive the greatest benefit.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 316 pp. Englisch.
Da: Majestic Books, Hounslow, Regno Unito
EUR 173,32
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand pp. xvi + 296 65 Figures.
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 173,01
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND pp. xvi + 296.